• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    2/8/24 4:31:10 PM ET
    $BGXX
    $BTAI
    $COEP
    $CRVS
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BGXX alert in real time by email

    Gainers

    • Xilio Therapeutics (NASDAQ:XLO) shares rose 10.5% to $0.66 during Thursday's after-market session. The market value of their outstanding shares is at $18.2 million.
    • Sensus Healthcare (NASDAQ:SRTS) stock increased by 9.58% to $4.0. The company's market cap stands at $65.5 million. The company's, Q4 earnings came out today.
    • Corvus Pharma (NASDAQ:CRVS) stock moved upwards by 8.49% to $2.17. The market value of their outstanding shares is at $106.4 million.
    • SenesTech (NASDAQ:SNES) shares moved upwards by 6.86% to $1.09.
    • Coeptis Therapeutics (NASDAQ:COEP) stock rose 6.2% to $0.51. The company's market cap stands at $17.3 million.
    • Bright Green (NASDAQ:BGXX) shares moved upwards by 4.99% to $0.18. The company's market cap stands at $32.8 million.

    Losers

    • BioXcel Therapeutics (NASDAQ:BTAI) stock fell 42.1% to $2.17 during Thursday's after-market session. The market value of their outstanding shares is at $64.9 million.
    • Renalytix (NASDAQ:RNLX) stock declined by 29.76% to $0.38. The company's market cap stands at $19.0 million.
    • Syra Health (NASDAQ:SYRA) stock fell 13.82% to $4.18. The company's market cap stands at $26.8 million.
    • SINTX Techs (NASDAQ:SINT) stock fell 10.56% to $0.14. The market value of their outstanding shares is at $1.2 million.
    • NanoString Technologies (NASDAQ:NSTG) stock declined by 8.96% to $0.11. The market value of their outstanding shares is at $5.0 million.
    • Pro-Dex (NASDAQ:PDEX) stock decreased by 8.28% to $19.5. The company's market cap stands at $69.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BGXX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BGXX
    $BTAI
    $COEP
    $CRVS

    CompanyDatePrice TargetRatingAnalyst
    BioXcel Therapeutics Inc.
    $BTAI
    3/17/2026$17.00Buy
    Rodman & Renshaw
    Sensus Healthcare Inc.
    $SRTS
    3/6/2026$7.50Buy
    Alliance Global Partners
    Corvus Pharmaceuticals Inc.
    $CRVS
    10/13/2025$16.00Overweight
    Barclays
    Xilio Therapeutics Inc.
    $XLO
    8/6/2025$2.00Outperform
    Leerink Partners
    Sensus Healthcare Inc.
    $SRTS
    1/31/2025$18.00Buy
    Lake Street
    Corvus Pharmaceuticals Inc.
    $CRVS
    1/2/2025$11.00Buy
    H.C. Wainwright
    Sensus Healthcare Inc.
    $SRTS
    11/15/2024$12.00 → $14.00Buy
    Maxim Group
    BioXcel Therapeutics Inc.
    $BTAI
    2/21/2024$9.00 → $4.00Buy → Neutral
    UBS
    More analyst ratings

    $BGXX
    $BTAI
    $COEP
    $CRVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $330,182 worth of shares (171,034 units at $1.93) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    3/17/26 8:10:19 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    CEO and President Mehta Vimal converted options into 383 shares, increasing direct ownership by 2% to 21,259 units (SEC Form 4)

    4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)

    3/16/26 8:05:59 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Steinhart Richard I converted options into 68 shares, increasing direct ownership by 1% to 6,645 units (SEC Form 4)

    4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)

    3/16/26 8:04:36 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGXX
    $BTAI
    $COEP
    $CRVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on BioXcel Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of BioXcel Therapeutics with a rating of Buy and set a new price target of $17.00

    3/17/26 8:16:49 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alliance Global Partners initiated coverage on Sensus Healthcare with a new price target

    Alliance Global Partners initiated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $7.50

    3/6/26 8:35:41 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Barclays initiated coverage on Corvus Pharmaceuticals with a new price target

    Barclays initiated coverage of Corvus Pharmaceuticals with a rating of Overweight and set a new price target of $16.00

    10/13/25 8:52:40 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGXX
    $BTAI
    $COEP
    $CRVS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for IGALMI issued to BIOXCEL THERAPEUTICS, INC.

    Submission status for BIOXCEL THERAPEUTICS, INC.'s drug IGALMI (ORIG-1) with active ingredient DEXMEDETOMIDINE has changed to 'Approval' on 04/05/2022. Application Category: NDA, Application Number: 215390, Application Classification: Type 3 - New Dosage Form

    4/6/22 2:18:32 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGXX
    $BTAI
    $COEP
    $CRVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting

    WALTHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 17-22, 2026 at the San Diego Convention Center in San Diego, California. Poster presentation details, as follows: Title: Discovery and Optimization of XTX601, a Masked Claudin 18.2-Targeting T Cell EngagerSession Category: ImmunologySession Title: T Cell Engagers 1Session Date and Time: Monday, Apr. 20, 2026, from 9:00 a.m. to 12:0

    3/17/26 4:45:00 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SenesTech Announces 2025 Financial Results Driven by Strong Growth in E-Commerce

    SURPRISE, Ariz., March 12, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, today announced financial results for the fourth quarter and the full year ended December 31, 2025. 2025 HighlightsRevenue increased by 20% to $2.2 million in 2025 as compared to 2024, driven by strong growth in the Company's overall e-commerce channels despite the impact associated with the Company's transition to directly managing Amazon sales of Evolve® Rat and Evolve Mouse. Excluding this transition-related impact, we estimate re

    3/12/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiated soquelitinib atopic dermatitis Phase 2 trial Completed public offering raising net proceeds of $189 million, extending cash runway into the second quarter of 2028 Conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended De

    3/12/26 4:01:00 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGXX
    $BTAI
    $COEP
    $CRVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $330,182 worth of shares (171,034 units at $1.93) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    3/17/26 8:10:19 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Sachetta Eric bought $7,620 worth of shares (2,000 units at $3.81), increasing direct ownership by 1% to 142,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    2/26/26 9:25:34 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $BGXX
    $BTAI
    $COEP
    $CRVS
    SEC Filings

    View All

    Corvus Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)

    3/13/26 8:46:18 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Corvus Pharmaceuticals Inc.

    424B5 - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)

    3/13/26 8:41:37 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by Corvus Pharmaceuticals Inc.

    S-3ASR - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)

    3/13/26 8:02:17 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGXX
    $BTAI
    $COEP
    $CRVS
    Financials

    Live finance-specific insights

    View All

    SenesTech Announces 2025 Financial Results Driven by Strong Growth in E-Commerce

    SURPRISE, Ariz., March 12, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, today announced financial results for the fourth quarter and the full year ended December 31, 2025. 2025 HighlightsRevenue increased by 20% to $2.2 million in 2025 as compared to 2024, driven by strong growth in the Company's overall e-commerce channels despite the impact associated with the Company's transition to directly managing Amazon sales of Evolve® Rat and Evolve Mouse. Excluding this transition-related impact, we estimate re

    3/12/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDa

    3/9/26 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

    SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 d

    3/5/26 4:01:00 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BGXX
    $BTAI
    $COEP
    $CRVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    11/14/24 7:25:52 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:12:23 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $BGXX
    $BTAI
    $COEP
    $CRVS
    Leadership Updates

    Live Leadership Updates

    View All

    SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

    Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX Technologies, Inc., effective March 16, 2026. Mr. Elmore most recently served as Core Business Director at Invibio, a division of Victrex plc. With more than 15 years of experience in advanced biomaterials and medical dev

    2/18/26 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting

    Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home Setting as Early as Year-End 2026 BioXcel Therapeutics on Track to Submit a sNDA for IGALMI® this Month NEW HAVEN, Conn., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced the advancement of its commercial planning for IGALMI® in the at-home setting. As part of this, Mark Pavao, a commercial planning and launch advisor with more than 3

    1/12/26 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care